Jing Si Herbal Tea as Adjuvant Treatment in Patients With Chronic Pelvic Pain Syndrome
JSHT-CPPS
JING SI HERBAL TEA Use as Adjuvant Treatment in Patients With Chronic Pelvic Pain Syndrome
2 other identifiers
interventional
400
1 country
1
Brief Summary
The purpose of this clinical trial is to evaluate the efficacy of Jing Si Herbal Tea as an adjuvant treatment for patients diagnosed with Chronic Pelvic Pain Syndrome (CPPS). The study aims to determine whether adding Jing Si Herbal Tea to standard care can improve clinical symptoms and quality of life in these patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Mar 2026
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 13, 2026
CompletedFirst Posted
Study publicly available on registry
January 21, 2026
CompletedStudy Start
First participant enrolled
March 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2030
February 4, 2026
February 1, 2026
3.8 years
January 13, 2026
February 2, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) Total Score
The NIH-CPSI is a standardized 9-item questionnaire used to assess symptom severity in patients with CPPS across three domains: Pain, Urinary Symptoms, and Quality of Life. The total score ranges from 0 to 43, with higher scores indicating more severe symptoms. Severity is categorized as Mild (0-14), Moderate (15-29), and Severe (30-43).
Baseline, Month 1, Month 2, Month 3, Month 6, and Month 12
Secondary Outcomes (2)
Change in Short Form 12 Health Survey (SF-12) Score
Baseline, Month 1, Month 2, Month 3, Month 6, and Month 12
Incidence of Adverse Events
Up to 12 months
Study Arms (2)
Jing Si Herbal Tea Group
EXPERIMENTALParticipants in this group will receive Jing Si Herbal Tea as an adjuvant therapy. They are instructed to take the tea orally twice daily (BID) - one pack in the morning and one in the evening - for a duration of 12 months.
Placebo Control Group
PLACEBO COMPARATORParticipants in this group will receive a matching placebo. They are instructed to take the placebo orally twice daily (BID) - one pack in the morning and one in the evening - for a duration of 12 months.
Interventions
Oral administration of a matching placebo, 2 packs daily (one in the morning and one in the evening) for 12 months. The placebo is identical in appearance and packaging to the investigational product.
Oral administration, 2 packs daily (one in the morning and one in the evening) for 12 months.
Eligibility Criteria
You may qualify if:
- Male patients.
- Diagnosed with Chronic Pelvic Pain Syndrome (CPPS) at the investigational site.
- Currently receiving continuous follow-up and medical treatment.
You may not qualify if:
- Female patients (Excluded because the standard treatment, alpha-blockers, is not approved or reimbursed by the National Health Insurance for this indication in women in Taiwan).
- Duration of symptoms less than 3 months.
- History of recurrent urinary tract infections.
- Diagnosed with malignancy.
- Hospitalization for other diseases within the past 3 months.
- Unwilling to participate in the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Taipei Tzu Chi Hospital
New Taipei City, 231, Taiwan
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Masking Details
- The placebo is identical in appearance and packaging to the investigational product to maintain the blind.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Attending Physician
Study Record Dates
First Submitted
January 13, 2026
First Posted
January 21, 2026
Study Start
March 1, 2026
Primary Completion (Estimated)
December 31, 2029
Study Completion (Estimated)
December 31, 2030
Last Updated
February 4, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be shared to protect participant privacy and confidentiality. The informed consent form signed by participants does not include provisions for the public release of individual-level data.